title: [Progress in immunotherapy for non-small cell lung cancer].
abstract: In recent years, the five-year survival rate of patients with advanced stage non-small cell lung cancer (NSCLC) remains low despite recent advances in surgery, irradiation, chemotherapy, and targeted therapy. Immunotherapy which utilizes the immune system to control and eradicate cancer is a viable treatment approach for malignancy. Immunotherapy in patients with lung cancer has made breakthrough progress recently. Novel immunotherapeutic agents, such as antigen-specific tumour vaccines, checkpoint inhibitors, etc, have all been evaluated in lung cancer, and some have shown prolonged survival time in phase II trials and III trails. The immune-related response criteria for the evaluation of antitumor responses with immunotherapeutic agents have been made. Now, immunotherapy will likely be a fundamentally new concept for the treatment of NSCLC.
authors.affiliation: Department of Respiratory Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Science  and Peking Union Medical College, Beijing 100730, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Xu
authors.affiliation: Department of Respiratory Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Science  and Peking Union Medical College, Beijing 100730, China.
authors.forename: Mengzhao
authors.initials: M
authors.lastname: Wang
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000628:therapy*; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008175:Lung Neoplasms / Q000628:therapy*; D016896:Treatment Outcome